ArticleClinical cancer research : an official journal of the American Association for Cancer Research2021
A Pan-Histone Deacetylase Inhibitor Enhances the Antitumor Activity of B7-H3-Specific CAR T Cells in Solid Tumors.
Open access · bronzeAbstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
3.9field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 58 citations in OpenAlex.
- T cell senescence and exhaustion: molecular mechanisms and immune rejuvenation for cancer immunotherapy.Signal transduction and targeted therapy · 2026Review
- Low dose radiotherapy-induced tumor-preferential antigens enhance antibody-drug conjugate efficacy in solid tumors.Neoplasia (New York, N.Y.) · 2026Article
- Novel approaches to modulate CAR-T cell function by targeting the tumor microenvironment in ovarian cancer.Journal of ovarian research · 2026Review
- Combining Small-Molecular Compounds With CAR T-Cell Therapy: Novel Strategies for Enhanced Cancer Immunotherapy.Cancer innovation · 2026Review
- HDAC inhibitors in cancer therapy: sensitization mechanisms, combination strategies, and translational challenges.Frontiers in cell and developmental biology · 2026Review
- Metabolic epigenome targeting hitsHaematologica · 2025Article
- Preclinical efficacy of combinatorial B7-H3 CAR T cells and ONC206 against diffuse intrinsic pontine glioma.bioRxiv : the preprint server for biology · 2025Article
- B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Preclinical application of a CD155 targeting chimeric antigen receptor T cell therapy for digestive system cancers.Oncogene · 2025Article
- Evolving CAR T-Cell Therapy to Overcome the Barriers in Treating Pediatric Central Nervous System Tumors.Cancer discovery · 2025Review
- Reprogramming the breast tumor immune microenvironment: cold-to-hot transition for enhanced immunotherapy.Journal of experimental & clinical cancer research : CR · 2025Review
- Advances in strategies to improve the immunotherapeutic efficacy of chimeric antigen receptor-T cell therapy for lymphoma.Cancer biology & medicine · 2025Review
- Challenges in the preclinical design and assessment of CAR-T cells.Frontiers in immunology · 2025Review
- Supercharging CAR-T cells through transcriptional and epigenetic armoring.Theranostics · 2025Review
- The relevance of B7-H3 and tumor-associated macrophages in the tumor immune microenvironment of solid tumors: recent advances.American journal of translational research · 2025Review
- Tumor Immunotherapy Targeting B7-H3: From Mechanisms to Clinical Applications.ImmunoTargets and therapy · 2025Review
- Advancements in adoptive CAR immune cell immunotherapy synergistically combined with multimodal approaches for tumor treatment.Bioactive materials · 2024Review
- Effects of a novel HDAC6-selective inhibitor's radiosensitization on cancer cells.Molecular biology reports · 2024Article
- Novel CAR-T Cells Specifically Targeting SIA-CIgG Demonstrate Effective Antitumor Efficacy in Bladder Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Radiomic features based on pyradiomics predict CD276 expression associated with breast cancer prognosis.Heliyon · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors at 6 institutions in 3 countries.
Xinyuan Lei *Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Guangzhou, China.
Zhanpeng Ou *Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Guangzhou, China.
Zhaohui Yang *Department of Oral and Maxillofacial Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
Jianglong Zhong *Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Guangzhou, China.
Yanliang Zhu *State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing, Jiangsu, China.
Jing TianDepartment of Ultrasound, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
Jiannan WuDepartment of Breast Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
Heran DengDepartment of Breast Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
Xinyu LinDepartment of Oral and Maxillofacial Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
Yu PengGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Guangzhou, China.
Bowen LiDepartment of Oral and Maxillofacial Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
Lile HeDepartment of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Zhiming TuDepartment of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Weixiong ChenDepartment of Oral and Maxillofacial Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
Qunxing LiGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Guangzhou, China.
Niu LiuGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Guangzhou, China.
Hanqing ZhangGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Guangzhou, China.
Zhangsong WangGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Guangzhou, China.
Zezhen FangDepartment of Oral and Maxillofacial Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
Teppei YamadaDepartment of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan.
Xiaobin LvNanchang Key Laboratory of Cancer Pathogenesis and Translational Research, Center Laboratory, the Third Affiliated Hospital, Nanchang University, Nanchang, China.
Tian TianDepartment of Neurobiology, Key Laboratory of Human Functional Genomics of Jiangsu, Nanjing Medical University, Nanjing, Jiangsu, China.
Guokai PanGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Guangzhou, China.
Fan WuDepartment of Oral and Maxillofacial Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
Liping XiaoDepartment of Oral and Maxillofacial Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
Lizao ZhangGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Guangzhou, China.
Tingting CaiGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Guangzhou, China.ORCID 0000-0003-1014-5636
Xinhui WangDepartment of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Bakhos A TannousExperimental Therapeutics and Molecular Imaging Lab, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Jinsong LiDepartment of Oral and Maxillofacial Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China. fansong2@mail.sysu.edu.cn SFERRONE@mgh.harvard.edu lijins@mail.sysu.edu.cn.
Filippos KontosDepartment of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-7011-4017
Soldano FerroneDepartment of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. fansong2@mail.sysu.edu.cn SFERRONE@mgh.harvard.edu lijins@mail.sysu.edu.cn.ORCID 0000-0003-2900-8834
Song FanGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Guangzhou, China. fansong2@mail.sysu.edu.cn SFERRONE@mgh.harvard.edu lijins@mail.sysu.edu.cn.
Sun Yat-sen University · CNMassachusetts General Hospital · USFukuoka University · JPNanjing Medical University · CNSoutheast University · CNThird Hospital of Nanchang · CN
Funding
T cell plasticity, fusion proteins and CAR T cell-based immunotherapy of head and neck cancerR01DE028172 · NIDCR · MASSACHUSETTS GENERAL HOSPITAL · PI WANG, XINHUI · 2018 to 2022
$1.9MIL-15 TRiKES-based specific immunotherapy of pancreatic ductal adenocarcinomaR03CA231766 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI FERRONE, CRISTINA R., FERRONE, SOLDANO · 2018 to 2019
$177kIL-15 TRiKES-based specific immunotherapy of TNBC; resistance mechanismsR03CA216114 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI FERRONE, SOLDANO, VALLERA, DANIEL A · 2018 to 2019
$177kSafety and anti-tumor activity of B7-H3 CAR T cells in TNBCR03CA223886 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI DOTTI, GIANPIETRO, FERRONE, SOLDANO · 2018 to 2019
$176kB7-H3 CAR T cell-based immunotherapy combined with Losartan to counteract desmoplasia for the treatment of Pancreatic Ductal Adenocarcinoma (PDAC)R03CA249542 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI FERRONE, CRISTINA R., FERRONE, SOLDANO · 2021 to 2021
$167kAdaptive immunotherapy of anaplastic thyroid cancerR03CA239193 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI PARANGI, SAREH · 2019 to 2020
$165kNCI NIH HHS R03 CA216114NCI NIH HHS R03 CA223886NCI NIH HHS R03 CA231766NCI NIH HHS R03 CA239193NCI NIH HHS R03 CA249542NIDCR NIH HHS R01 DE028172
Abstract
purposeThe limited efficacy of chimeric antigen receptor (CAR) T-cell therapies with solid malignancies prompted us to test whether epigenetic therapy could enhance the antitumor activity of B7-H3.CAR T cells with several solid cancer types. EXPERIMENTAL
designWe evaluated B7-H3 expression in many human solid cancer and normal tissue samples. The efficacy of the combinatorial therapy with B7-H3.CAR T cells and the deacetylase inhibitor SAHA with several solid cancer types and the potential underlying mechanisms were characterized with
resultsB7-H3 is expressed in most of the human solid tumor samples tested, but exhibits a restricted expression in normal tissues. B7-H3.CAR T cells selectively killed B7-H3 expressing human cancer cell lines
conclusionsOur results show that our novel strategy which combines SAHA and B7-H3.CAR T cells enhances their therapeutic efficacy with solid cancers and justify its translation to a clinical setting.
Indexed as
B7 AntigensImmunotherapy, AdoptiveAnimalsCombined Modality TherapyHistone Deacetylase InhibitorsHumansMiceNeoplasmsReceptors, Chimeric AntigenTumor Cells, CulturedB7 AntigensCD276 protein, humanHistone Deacetylase InhibitorsReceptors, Chimeric Antigen
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.